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STS score 10.64.5 13.035.4 0.006
CAD>50% 82.9% 50.0% 0.004Pre BAV LV EF% 40.716.8 49.415.2 <0.001
Max. balloon diameter, mm 24.41.35 21.92.1 <0.001
Mean AV gradient change post
BAV, mmHg21.3811.40 26.3814.65 0.01In hospital stroke 1.5% 1.3% 1.00VARC minor bleed 3.1% 0 0.04VARC stage 3 AKI 3.3% 0 0.05In hospital Death 5.6% 5.3% 0.9030 day mortality 5.9% 10.6% 0.13One year mortality 34.2% 28.5% 0.3V
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Background: The frequency and signiﬁcance of adverse events (AE) reported with
transcatheter aortic valve replacement (TAVR) using Edwards SAPIEN THV in the
voluntary, publicly available MAUDE database has not been characterized.
Methods: The FDA MAUDE Database was queried for all reported events relating
to Edwards SAPIEN TAVR through Oct. 2013. Data was reported on a quarterly
basis using the MAUDE classiﬁcation system. AE reports from 10/2011 through 4/
2012 were categorized based on the Valve Academic Research Consortium (VARC)
classiﬁcation system.
Results: 1222 total AE reports were found (MAUDE categories: death n¼234,
injury n¼921, malfunction n¼67) with a signiﬁcant increase over the ﬁrst 5 analyzed
quarters with stabilization in the ﬁnal 3 quarters (ﬁg 1). Of the 103 consecutive AEs
analyzed, 69 were classiﬁable by VARC and 34 were not (table 1).
Conclusion: Despite the limitations of this voluntary database, AE reports have
increased since FDA approval of the Edwards SAPIEN THV, but have leveled off in
2013. The utility of the database to assess real-world AEs could be improved by the
routine use of an accepted AE classiﬁcation system.CRT-712
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Background: The improvement of the left ventricular ejection fraction (LVEF) in
patients with impaired left ventricular function and severe aortic stenosis (AS) after
transcatheter aortic valve replacement (TAVR) is highly variable. Prolonged QRS
duration (QRSd) and decreased QRS amplitude (QRSa) are associated with impaired
left ventricular function. This study is to assess the predictive values of baseline QRSd
and QRSa on improvement of LVEF in patients with reduced LVEF and severe AS
after TAVR.
Methods: Baseline ECGs and serial echocardiograms of 96 consecutive patients with
LVEF < 45% who underwent TAVR using Edwards-SAPIEN (94%) and CoreValve
(6%) and survived to hospital discharge between 2007 and 2013 in our hospital were
reviewed.
Results: Patients with QRSd145ms(n¼48) had higher incidence of left bundle
branch block (26.2%), permanent right ventricular pacemaker implantation(50%) and
lower incidence of intraventricular conduction delay(16.7%) as compared to those with
QRS<145ms (7.1% , 4.7% and 50%) respectively. 17(17.7%) patients had low QRSa
(<5mm on lime leads or <10mm on precordial leads) with 9(53%) patients with
QRS145ms. After a mean of 12 14months, the patients with ORSd<145ms had a
signiﬁcant increase of LVEF (15.53.5%) vs no signiﬁcant change (4.0 4.0%) in
those with QRSd 145ms. By Receiver Operating Characteristic analysis, the QRSd
of 145ms and normal QRSa were determined as the optimal criteria for predicting the
improvement of LVEF after TAVR. The probability of increasing LVEF by at least
10% was 7613% and 1912% for patients with QRSd < and  145 ms respectively.
The sensitivity and speciﬁcity of using QRSd ¼ 145ms and normal QRSa as predictor
for signiﬁcant increase in LVEF were 80% and 77% respectively. The p-value from the
paired t-test of pre- and post-EF for patients with QRSd < and  145ms was 3.85E-
11 and 0.02 respectively.
Conclusion: Among patients with LVEF below 45% and severe AS undergoing
TAVR, the baseline QRSd and QRSa accurately predict signiﬁcant improvement of
left ventricular function. A vast majority of the subjects with QRSd < 145ms and
normal QRSa have a 10% or more improvement of LVEF after TAVR.
